BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Horizon Discovery Ltd. and The Institute of Cancer Research (ICR) to Collaborate on Genome-Wide Synthetic Lethality Screens


9/9/2010 2:17:11 PM

September 08, 2010 -- Horizon Discovery (Horizon) and the Institute of Cancer Research (ICR) are forming a collaboration aimed at rapidly screening the human genome for novel drug targets that selectively kill cancer cells.

By combining Horizon’s panel of 200-plus genetically-defined ‘X-MAN’ cancer models (cellular model that harbors cancer-causing genetic mutations along with a matched-normal parental cell) with ICR scientist Professor Alan Ashworth’s world-class expertise in genome-wide functional genomics, the collaborators endeavor to uncover genetic weak-spots in cancer cells enabling their selective targeting by anti-cancer agents.

Professor Ashworth, Director of the Breakthrough Breast Cancer Research Centre at the ICR, has elegantly demonstrated this concept of ‘synthetic lethality’ previously with his discovery that PARP-inhibitors show dramatic selectivity for breast cancers carrying mutant BRCA genes. PARP-inhibitors are now showing great promise in early-stage clinical trials on patients carrying defective BRCA genes.

Horizon’s co-founder Dr Chris Torrance, while in the renowned Vogelstein laboratory at Johns Hopkins University, has also demonstrated the power of using genetically-defined tumour versus normal (isogenic) human cell-line pairs to rapidly perform synthetic lethality screens on specific cancer-causing genetic lesions.

Together, Professor Ashworth and Horizon will build a high-throughput synthetic lethality screening platform based on the latest generation of pooled shRNA libraries and deep-sequencing technologies. By deploying X-MAN isogenic cell-lines in such screens, a focused list of genome targets that represent key nodes of therapeutic intervention in specific cancer patient populations will be identified.

ICR and Horizon also intend to use a comprehensive ‘personalised’ cancer-target hunting capability in collaboration with other companies who wish to rapidly identify new targets and biomarkers that may effectively address specific patient cohorts. This could enable the more rapid and successful translation of oncology drug candidates into clinical use.

Professor Ashworth says: “We are excited by the opportunity offered by this collaboration between the ICR and Horizon of combining two cutting-edge technologies. We are confident that the synergy between these two partners will enable us to move projects from the laboratory bench to the bedside very rapidly.”

Dr Chris Torrance, CEO of Horizon Discovery Ltd, says: “We are proud to be working with Alan’s lab to build a comprehensive picture of synthetically lethal targets, which have proven ability to effectively attack cancer at its causative roots. Moreover, we will use the X-MAN models to more effectively deconstruct the many important cancer genotypes for which conventional pharma drug discovery pipelines have still not yielded viable drug candidates or targets, such as mutant K-Ras and p53. Such genes are major drivers of cancer development and their resistance to existing therapies.”



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES